Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia
1997

Ibandronate for Treating High Calcium Levels in Cancer Patients

Sample size: 147 publication Evidence: high

Author Information

Author(s): SH Ralston, D Thi6baud, Z Herrmann, EU Steinhauer, B Thurlimann, J Walls, MR Lichinitser, R Rizzoli, H Hagberg, HJ Huss, M Tubiana-Hulin, JJ Body

Primary Institution: University of Aberdeen, UK

Hypothesis

Higher doses of ibandronate will be more effective in treating cancer-associated hypercalcaemia.

Conclusion

Ibandronate is a safe and effective treatment for cancer-associated hypercalcaemia, with higher doses leading to better outcomes.

Supporting Evidence

  • Serum calcium values fell progressively in each group from day 2, reaching a nadir at day 5.
  • 50% of patients in the 2-mg group achieved serum calcium values below 2.7 mm compared to 75.6% in the 4-mg group and 77.4% in the 6-mg group.
  • Ibandronate was generally well tolerated with no serious drug-related adverse events observed.

Takeaway

This study shows that a medicine called ibandronate can help lower high calcium levels in cancer patients, especially when given in higher amounts.

Methodology

A multicentre double-blind randomized trial comparing three doses of intravenous ibandronate in patients with cancer-associated hypercalcaemia.

Potential Biases

Potential bias due to the exclusion of patients who had received prior treatments.

Limitations

Patients with significant renal impairment or other causes of hypercalcaemia were excluded, which may limit the generalizability of the results.

Participant Demographics

147 patients with severe cancer-associated hypercalcaemia, with a mix of tumour types including breast and haematological cancers.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication